Clinical Trial

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Study acronym: LoCaMoTE-PD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 5 locations 2026-08-07
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07005180
Lead Sponsor Hillhurst Biopharmaceuticals, Inc.
Collaborators: The Parkinson Study Group, Massachusetts General Hospital (PI: Michael Schwarzschild MD,PhD, Co-PI: Stephen Gomperts MD,PhD), Michael J. Fox Foundation for Parkinson's Research
Conditions Parkinson Disease
Enrollment 36 participants
Start Date 2026-06-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10